Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) has provided an announcement.
WuXi XDC Cayman Inc. has formally dispatched the composite offer and response document for its voluntary conditional cash offers to acquire all issued shares of TOT BIOPHARM International Co. Ltd., excluding those already held or agreed to be acquired by the offeror and its concert parties, and to cancel all outstanding share options. The despatch, which includes the offer terms, timetable and independent advice to shareholders and option holders, sets 12 February 2026 as the commencement date of the offers and outlines key deadlines through mid‑March, marking a key step in the proposed takeover process and giving investors a defined window to consider and respond to the bid.
The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.
More about TOT BIOPHARM International Co. Ltd.
TOT BIOPHARM International Co. Ltd. operates in the biopharmaceutical sector, focusing on the development and commercialization of oncology and other biologic therapies, and is listed on the Hong Kong Stock Exchange. The company targets both domestic and international markets with a portfolio of innovative drugs and related services aimed at addressing unmet medical needs.
Average Trading Volume: 2,932,065
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.25B
See more insights into 1875 stock on TipRanks’ Stock Analysis page.